OptimizeRx Corporation OPRX
9.33 USD -0.08 (-0.85%)
At closeNov 3, 2026, 4:00 PM EST
9.33 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
9.24 Day range 9.43
4.54 52-week range 19.69
- YTD
- -23.90%
- 1 year
- -52.01%
- Market cap
- 175.74M
- Revenue (ttm)
- 88.18M
- Profit margin
- -27.41%
- EPS (ttm)
- 0.24
- Shares out
- 18.42M
- P/E ratio
- 38.88
- Forward P/E
- 9.86
- YTD return
- -23.90%
- 1-year return
- -52.01%
- Volume
- 94.55K
- Avg volume
- 181.06K
- Open
- 9.41
- Previous close
- 9.41
- Day's range
- 9.24 – 9.43
- 52-week range
- 4.54 – 19.69
- Analysts
- Buy
- Price target
- 10.36 (+11.0%)
2Y +4.12 (+79.08%)
Key statistics
- Enterprise value
- 118.13M
- PEG ratio
- 0.00
- Price / sales
- 1.01
- Price / book
- 0.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 30.50%
- Free cash flow
- 8.35M
- Total cash
- 16.13M
- Total debt
- 35.72M
- Return on equity
- -20.97%
- Short % of float
- 5.68%
- 50-day average
- 5.40
- 200-day average
- 8.91
Analyst view
Consensus: buy
Buy
Price target (mean) 10.36 +11.0% upside
Now 9.33
- Target (low)
- 5.50
- Target (mean)
- 10.36
- Target (high)
- 17.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy3
- Buy4
- Hold1
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.25.
Financials — quick view
OPRX Revenue — quarterly 20.50M
OPRX Net income — quarterly -703.00K
OPRX EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.06 | 0.12 | +0.06 | +100.00% |
| Aug 8, 2024 | Jun 1, 2024 | -0.07 | 0.02 | +0.09 | +128.57% |
| May 14, 2024 | Mar 1, 2024 | -0.11 | -0.11 | 0.00 | 0.00% |
| Apr 16, 2024 | Dec 1, 2023 | 0.00 | 0.26 | — | — |
| Nov 6, 2023 | Sep 1, 2023 | 0.02 | 0.09 | +0.07 | +350.00% |
| Aug 14, 2023 | Jun 1, 2023 | -0.02 | -0.01 | +0.01 | +50.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Stephens & Co. | init | — | Equal-Weight |
| Nov 14, 2024 | RBC Capital | main | Outperform | Outperform |
| Nov 14, 2024 | Roth MKM | reit | Buy | Buy |
| Nov 14, 2024 | Stifel | main | Buy | Buy |
| Nov 14, 2024 | Barclays | main | Equal-Weight | Equal-Weight |
| Nov 14, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
About OptimizeRx Corporation
OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- optimizerx.com
News
OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET 
OptimizeRx and PulsePoint Partner to Connect HCP Media Across the Funnel 
B. Riley Securities Maintains Buy on OptimizeRx, Raises Price Target to $11 
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? 
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath 
OptimizeRx: Gross Margin Gains And Improved Long-Term Outlook 
Reviewing OptimizeRx (NASDAQ:OPRX) & Aclarion (NASDAQ:ACON) 
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence 
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference 
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor
Your note
Sign in to keep a note on OPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BESCH DOUG | Officer | Conversion of Exercise of derivative security | Dec 18, 2024 | 11,583 |
| FEBBO WILLIAM J | Chief Executive Officer | Purchase | Dec 11, 2024 | 601,253 |
| KLEMA CATHERINE M | Director | Stock Award(Grant) | Jun 6, 2024 | 6,643 |
| LANG JAMES PAUL | Director | Stock Award(Grant) | Jun 6, 2024 | 68,044 |
| ODENCE-FORD MARION K. | General Counsel | Conversion of Exercise of derivative security | Dec 18, 2024 | 27,230 |
| SILVESTRO STEPHEN L | Officer | Conversion of Exercise of derivative security | Dec 18, 2024 | 80,848 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| First Light Asset Management, LLC | 14.98% | 1,811,611 | 8.75M | Sep 29, 2024 |
| Blackrock Inc. | 10.54% | 1,274,761 | 6.16M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 8.86% | 1,071,832 | 5.18M | Sep 29, 2024 |
| Samjo Management, LLC | 8.64% | 1,044,800 | 5.05M | Sep 29, 2024 |
| Vanguard Group Inc | 7.88% | 952,893 | 4.60M | Sep 29, 2024 |
| Blair (William) & Company, L.L.C. | 5.60% | 677,094 | 3.27M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 4.19% | 506,691 | 2.45M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 3.75% | 453,848 | 2.19M | Oct 30, 2024 |
| Jacob Internet Fund | 2.30% | 278,275 | 1.34M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 2.23% | 270,268 | 1.31M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.51% | 182,433 | 881.15K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 1.29% | 156,029 | 753.62K | Oct 30, 2024 |